摘要:
The invention relates to new triphenylimidazolyloxyalkanoic acids of the general formula I ##STR1## and a process for the treatment of thromboembolic, inflammatory and/or atherosclerotic diseases in humans by using the same.
摘要:
The invention relates to new 6-{5-[.omega.-(1-imidazolyl)-alkyl]-thien-2-yl}-3-oxo-2,3,4,5-tetrahydro-pyridazines having the general formula I ##STR1## and acid addition salts thereof and to a process for the treatment of inflammatory, atherosclerotic and thrombo-embolic diseases especially in humans.
摘要:
The invention relates to new 6-{4-(.omega.-(1-imidazolyl)-alkyl)-phenyl}-3-oxo-2,3,4,5-tetrahydro-pyridazines having the general formula I ##STR1## and acid addition salts thereof, and to a process for the treatment of inflammatory, atherosclerotic and thromboembolic diseases especially in humans.
摘要:
The invention relates to new imidazolylalkylthienyltetrahydropyridazines of the general formula I ##STR1## their acid addition salts as well as processes for their use in the treatment of cardiovascular and/or thromboembolic illnesses in humans.
摘要:
The invention relates to a new process for the treatment of hypertension and thromboembolic diseases in humans by simultaneous administration of (.+-.)- or (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene hydrochloride on the one side, and 4,5-dihydro-6-[4-(1-imidazolyl)-phenyl]-5-methyl-3(2H)-pyridazinone or 4,5-dihydro-6-[4-(1-imidazolyl)-thien-2-yl]-5-methyl-3(2H)-pyridazinone, on the other side, as the active substances.
摘要:
The present invention is directed to new, an imidazole group containing 2(1H)-pyridones of formula I ##STR1## salts thereof and process for treating congestive heart failure in humans.
摘要:
The present invention relates to new 6-[Imidazolyl-phenyl]-5-methyl-3-oxo-tetrahydropyridazines of the general formula I ##STR1## as well as their acid addition salts, methods for their use, and pharmaceutical preparations containing them.
摘要:
The invention relates to a new process for the treatment of hypertension and thromboembolic diseases in humans by simultaneous administration of (.+-.)- or (-)-2-[1-(2,6-dichlorophenoxy)-ethyl]-1,3-diazacyclopent-2-ene hydrochloride on the one side, and 4,5-dihydro-6-[4-(1-imidazolyl)-phenyl]-5-methyl-3(2H)-pyridazinone or 4,5-dihydro-6-[4-(1-imidazolyl)-thien-2-yl]-5-methyl-3(2H)-pyridazinone, on the other side, as the active substances.